BioCentury
ARTICLE | Product Development

FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

With little difference in efficacy or price, the CGRP competition will boil down to delivery, frequency and access

February 22, 2020 1:38 AM UTC
Updated on Feb 22, 2020 at 4:05 AM UTC

FDA's approval of Vyepti eptinezumab-jjmr from Lundbeck is the first for an IV-delivered CGRP inhibitor for migraine prevention, but the therapy will face competition from established subcutaneous drugs in its class.

Already on the market are CGRP inhibitors Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), as well as Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN), which targets the CGRP receptor rather than the ligand (see Table: “Comparisons of CGRP-targeted mAbs”)...

BCIQ Company Profiles

H. Lundbeck A/S